ARCHIVES

Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression

This article is from The Cancer Letter archive.

Vol. 35 No. 11 | November 30, 2012

Download PDF Visit The Full Archive

Related Articles

Two former Bristol-Myers Squibb executives were indicted as the company agreed to pay $300 million to investors.

June 17, 2005

AACI Opposes Most Guidelines Proposals But Can’t Agree On Research Based Ceiling

May 2, 1980

Phase III Nexavar Trial Fails Primary Endpoint

August 29, 2014

Severe Shortages Of Many Cancer Drugs Affecting Practices

November 19, 2010

Braun Named Executive Director Of ASCO Foundation

November 17, 2006

In Brief: Nobel Laurate Joshua Lederberg to Replace Schmidt As President’s Cancer Panel Chairman

June 1, 1979